Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I

Ebenezer Ojo, Zied Hosni, Iyke Onyemelukwe, Lennart Ramakers, Ian Houson, Alastair Florence

Research output: Contribution to conferencePoster

8 Downloads (Pure)

Abstract

Why the considerations for Lamivudine?
* Increasing numbers of HIV/AIDS infections on yearly basis (2.1 million new cases in 2015, UNAIDS)
* Hepatitis B infections (257 million cases globally, WHO)
* Currently FDA-approved antiretroviral therapy for the prevention and treatment of both viral infections (FDA).

Key research considerations and interests
To the best of our knowledge, no publication yet exists on continuous manufacturing of stable Lamivudine form 1. The key research question here is:
* Translate current batch crystallisation into a continuous process?
* Improve the downstream process-ability by modifying the particle properties?
* Develop miniaturise platforms for accelerated process development?
Original languageEnglish
Number of pages1
DOIs
Publication statusPublished - 9 Jul 2019
Event50th Annual Conference of the British Association of Crystal Growth - London, United Kingdom
Duration: 9 Jul 201911 Jul 2019

Conference

Conference50th Annual Conference of the British Association of Crystal Growth
CountryUnited Kingdom
CityLondon
Period9/07/1911/07/19

Keywords

  • autonomous platform
  • crystallisation
  • anti-retroviral
  • Lamivudine
  • process development

Fingerprint Dive into the research topics of 'Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I'. Together they form a unique fingerprint.

  • Cite this

    Ojo, E., Hosni, Z., Onyemelukwe, I., Ramakers, L., Houson, I., & Florence, A. (2019). Developing process understanding for continuous manufacturing of Lamivudine (Epivir®) Stable Form I. Poster session presented at 50th Annual Conference of the British Association of Crystal Growth, London, United Kingdom. https://doi.org/10.6084/m9.figshare.9775382.v1